Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Inside Health Policy, in “Gottlieb Issues Fewer Guidances and Delays Some Key Rules, But Hasn’t Chopped Any Yet,” by Nicholas Florko. (Read the full version – subscription required.)
Following is an excerpt:
Part of that smart regulatory approach may be a cautious stance with guidance documents. One FDA-watcher noted a downturn in the number of guidances coming out of the agency since Gottlieb took the helm. “Frankly during the Trump Administration, and since Commissioner Gottlieb took office, there has been very little new guidance actually issued,” Brad Thompson, attorney at Epstein, Becker & Green, told IHP. …
But Thompson did not see the lull in guidances as troubling. “[T]hat’s not surprising, because it will take some time for the new Gottlieb administration to review and put its mark on the various policy issues that have been making their way through FDA,” Thompson told IHP.
